Skip to main content
Journal cover image

Cardiovascular Safety of Azithromycin in Patients Hospitalized With COVID-19: A Prespecified Pooled Analysis of the COALITION I and COALITION II Randomized Clinical Trials.

Publication ,  Journal Article
Furtado, RHM; Barros E Silva, PGM; Fonseca, HAR; Serpa-Neto, A; Correa, TD; Guimarães, HP; Pereira, AJ; Olivato, GB; Zampieri, FG; Lisboa, T ...
Published in: Am J Cardiol
March 1, 2024

The cardiovascular safety from azithromycin in the treatment of several infectious diseases has been challenged. In this prespecified pooled analysis of 2 multicenter randomized clinical trials, we aimed to assess whether the use of azithromycin might lead to corrected QT (QTc) interval prolongation or clinically relevant ventricular arrhythmias. In the COALITION COVID Brazil I trial, 667 patients admitted with moderate COVID-19 were randomly allocated to hydroxychloroquine, hydroxychloroquine plus azithromycin, or standard of care. In the COALITION COVID Brazil II trial, 447 patients with severe COVID-19 were randomly allocated to hydroxychloroquine alone versus hydroxychloroquine plus azithromycin. The principal end point for the present analysis was the composite of death, resuscitated cardiac arrest, or ventricular arrhythmias. The addition of azithromycin to hydroxychloroquine did not result in any prolongation of the QTc interval (425.8 ± 3.6 ms vs 427.9 ± 3.9 ms, respectively, mean difference -2.1 ms, 95% confidence interval -12.5 to 8.4 ms, p = 0.70). The combination of azithromycin plus hydroxychloroquine compared with hydroxychloroquine alone did not result in increased risk of the primary end point (proportion of patients with events at 15 days 17.2% vs 16.0%, respectively, hazard ratio 1.08, 95% confidence interval 0.78 to 1.49, p = 0.65). In conclusion, in patients hospitalized with COVID-19 already receiving standard-of-care management (including hydroxychloroquine), the addition of azithromycin did not result in the prolongation of the QTc interval or increase in cardiovascular adverse events. Because azithromycin is among the most commonly prescribed antimicrobial agents, our results may inform clinical practice. Clinical Trial Registration: NCT04322123, NCT04321278.

Duke Scholars

Published In

Am J Cardiol

DOI

EISSN

1879-1913

Publication Date

March 1, 2024

Volume

214

Start / End Page

18 / 24

Location

United States

Related Subject Headings

  • SARS-CoV-2
  • Randomized Controlled Trials as Topic
  • Long QT Syndrome
  • Hydroxychloroquine
  • Humans
  • Electrocardiography
  • Cardiovascular System & Hematology
  • COVID-19 Drug Treatment
  • COVID-19
  • Azithromycin
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Furtado, R. H. M., Barros E Silva, P. G. M., Fonseca, H. A. R., Serpa-Neto, A., Correa, T. D., Guimarães, H. P., … COALITION COVID-19 Brazil Steering Committee and Investigators. (2024). Cardiovascular Safety of Azithromycin in Patients Hospitalized With COVID-19: A Prespecified Pooled Analysis of the COALITION I and COALITION II Randomized Clinical Trials. Am J Cardiol, 214, 18–24. https://doi.org/10.1016/j.amjcard.2023.11.069
Furtado, Remo H. M., Pedro G. M. Barros E Silva, Henrique A. R. Fonseca, Ary Serpa-Neto, Thiago D. Correa, Hélio P. Guimarães, Adriano J. Pereira, et al. “Cardiovascular Safety of Azithromycin in Patients Hospitalized With COVID-19: A Prespecified Pooled Analysis of the COALITION I and COALITION II Randomized Clinical Trials.Am J Cardiol 214 (March 1, 2024): 18–24. https://doi.org/10.1016/j.amjcard.2023.11.069.
Furtado RHM, Barros E Silva PGM, Fonseca HAR, Serpa-Neto A, Correa TD, Guimarães HP, et al. Cardiovascular Safety of Azithromycin in Patients Hospitalized With COVID-19: A Prespecified Pooled Analysis of the COALITION I and COALITION II Randomized Clinical Trials. Am J Cardiol. 2024 Mar 1;214:18–24.
Furtado, Remo H. M., et al. “Cardiovascular Safety of Azithromycin in Patients Hospitalized With COVID-19: A Prespecified Pooled Analysis of the COALITION I and COALITION II Randomized Clinical Trials.Am J Cardiol, vol. 214, Mar. 2024, pp. 18–24. Pubmed, doi:10.1016/j.amjcard.2023.11.069.
Furtado RHM, Barros E Silva PGM, Fonseca HAR, Serpa-Neto A, Correa TD, Guimarães HP, Pereira AJ, Olivato GB, Zampieri FG, Lisboa T, Junqueira DLM, Lapa MG, Monfardini F, Damiani LP, Echenique LS, Gebara OE, Hoffman Filho CR, Polanczyk CA, Rohde LE, Amazonas R, Machado FR, Avezum A, Azevedo LCP, Veiga VC, Rosa RG, Lopes RD, Cavalcanti AB, Berwanger O, COALITION COVID-19 Brazil Steering Committee and Investigators. Cardiovascular Safety of Azithromycin in Patients Hospitalized With COVID-19: A Prespecified Pooled Analysis of the COALITION I and COALITION II Randomized Clinical Trials. Am J Cardiol. 2024 Mar 1;214:18–24.
Journal cover image

Published In

Am J Cardiol

DOI

EISSN

1879-1913

Publication Date

March 1, 2024

Volume

214

Start / End Page

18 / 24

Location

United States

Related Subject Headings

  • SARS-CoV-2
  • Randomized Controlled Trials as Topic
  • Long QT Syndrome
  • Hydroxychloroquine
  • Humans
  • Electrocardiography
  • Cardiovascular System & Hematology
  • COVID-19 Drug Treatment
  • COVID-19
  • Azithromycin